🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSELECT trial: semaglutide 2.4mg cardiovascular outcomes — what worked for you? Page 3

SELECT trial: semaglutide 2.4mg cardiovascular outcomes — what worked for you?

TinaHashiRN Tue, Feb 11, 2025 at 9:47 PM 14 replies 1,676 viewsPage 3 of 3
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Feb 18, 2025 at 4:39 AM#11
Dr.KarenChen said:
The mechanism that matters here is not stomach emptying, it is central.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

43 16pam_stl, wei_SG, cory_ATX and 40 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Feb 18, 2025 at 7:10 PM#12
laura_annarbor said:
Agreed, though "tolerable" needs defining.

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

44 17maya_sedona, stefan_berlin, Dr.EM_Chicago and 41 others
Reply Quote Save Share Report
MariaRD
Member
823
4,567
Jun 2024
New Mexico
Feb 19, 2025 at 9:41 AM#13
Dr.KarenChen said:
The mechanism that matters here is not stomach emptying, it is central.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

45 18maria_elpaso, anders_CPH, Dr.NutriCornell and 42 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Feb 20, 2025 at 12:11 AM#14
TinaHashiRN said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
46 19Dr.LeslieOBGYN, MikeNYC_runner and 43 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 20, 2025 at 2:41 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.

47 20PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register